Videos

Aaron Gerds, MD, MS, discusses the MOMENTUM study and the potential role of momelotinib in the myelofibrosis treatment landscape.

A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.

A comprehensive overview of ruxolitinib, fedratinib, and pacritinib, the approved therapies for the treatment of myelofibrosis.

Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.

Chung-Han Lee, MD, PhD, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma.

Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.

Seth Wander, MD, PhD, discusses what research and topics excite him when looking to further evaluate future treatments for patients with breast cancer.

Laura A. Dawson, MD, FRCPC, discusses quality-of-life outcomes from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib versus sorafenib alone in hepatocellular carcinoma.

Gene Finley, MD, discusses his hopes for the small cell lung cancer field and what he hopes research focuses on in coming years.

Thoughtful comments from Dr Hussein Tawbi on setting first-line treatment goals and typical treatment responses in patients with unresectable or metastatic melanoma.

Clinical insights regarding the treatment of patients with BRAF-mutated metastatic melanoma presenting with symptomatic/asymptomatic brain metastases.

Neeta Somaiah, MD, discusses her presentation given at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.

Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

John Diaz, MD, discusses some of the targeted therapies that are showing promise for patients with ovarian cancer.

An expert on hematologic malignancies discusses the prognostic factors and molecular pathways involved in myelofibrosis.

Aaron Gerds, MD, MS, explains the types, presentations, and classic symptoms of myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.

Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.

Sagar Lonial, MD, FACP, provides an overview of the potential treatment options for patients with relapsed/refractory multiple myeloma.

Samuel Klempner, MD, discusses zolbetuximab for patients with claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.

Expert hematologist, Stephen Oh, MD, PhD, talks about unmet needs and promising new therapies in myelofibrosis.

Stephen Oh, MD, PhD, describes the factors that influence treatment selection in myelofibrosis, and then reviews sequencing strategies.

An overview of momelotinib, which was recently submitted for FDA approval, and how myelofibrosis treatments affect quality of life.

Stephen Oh, MD, PhD, gives a comprehensive review of the available treatment options for myelofibrosis.

An expert hematologist discusses important molecular targets in myelofibrosis, and when to consider transplant.

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the importance of long-term survivorship care and its correlation with quality-of-life in patients with thyroid cancer.

Giuseppe Curigliano, MD, discussed next steps following the HER2CLIMB study in HER2-positive breast cancer.

New research of the BTK degrader NX-2127 shows promising results for breaking down resistance to the therapy in the lymphoma and leukemia settings.

Gene G. Finley, MD, discusses the challenges that community oncologists are facing with small cell lung cancer treatment.

Revisiting the patient case study, Dr Hussein Tawbi shares how he might approach systemic first-line treatment in this situation, with a focus on limiting drug toxicity.